Compare TUYA & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TUYA | MLTX |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2021 | 2020 |
| Metric | TUYA | MLTX |
|---|---|---|
| Price | $2.01 | $18.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $3.49 | ★ $27.50 |
| AVG Volume (30 Days) | ★ 1.0M | 729.6K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.76 | N/A |
| Revenue Next Year | $11.90 | N/A |
| P/E Ratio | $27.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.87 | $5.95 |
| 52 Week High | $2.88 | $62.75 |
| Indicator | TUYA | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 54.45 |
| Support Level | N/A | $15.89 |
| Resistance Level | $2.48 | $19.24 |
| Average True Range (ATR) | 0.09 | 0.84 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 40.85 | 57.70 |
Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness. All the Group's revenue are derived from within the PRC.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.